长春碱与α-干扰素-2a联合方案治疗转移性肾细胞癌

Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma.

作者信息

Palmeri S, Gebbia V, Russo A, Gebbia N, Rausa L

机构信息

Sezione di Oncologia Clinica, Policlinico, Università di Palermo.

出版信息

Tumori. 1990 Feb 28;76(1):64-5. doi: 10.1177/030089169007600117.

DOI:10.1177/030089169007600117

PMID:2321276

Abstract

Thirteen patients with histologically proven advanced and/or metastatic renal cell carcinoma (RCC) were treated with vinblastine (Velbe, Eli Lilly, Sesto Fiorentino, Italy) and interferon-alpha-2a (Roferon-A, Roche, Milan). Eleven out of 13 patients were evaluable. Eighteen percent of patients had partial response, 46% stable disease (SD), and 36% progressive disease (PD). The mean survival of responders was 228+ days, whereas the patients showing SD and PD had a mean survival of 154+ and 107+ days respectively. Toxicity, including influenza-like syndrome, fever, neurological and gastrointestinal side effects, was generally mild. However, medication with paracetamol was required in 82% of cases. Our small study confirms that VBL and IFN-2a regimen is moderately active in RCC.

摘要

13例经组织学证实为晚期和/或转移性肾细胞癌（RCC）的患者接受了长春碱（Velbe，礼来公司，意大利佛罗伦萨塞斯托）和α-2a干扰素（Roferon-A，罗氏公司，米兰）治疗。13例患者中有11例可评估。18%的患者有部分缓解，46%病情稳定（SD），36%病情进展（PD）。缓解者的平均生存期为228 +天，而病情稳定和进展的患者平均生存期分别为154 +天和107 +天。包括流感样综合征、发热、神经和胃肠道副作用在内的毒性一般较轻。然而，82%的病例需要使用对乙酰氨基酚进行药物治疗。我们的小型研究证实，长春碱和干扰素-2a方案在肾细胞癌中具有中度活性。